Reply - 03/03/22

Doi : 10.1016/j.jaci.2021.12.763

Mingzhu Jin, MD ^a,^b, Simon Watkins, PhD ^c, Yolanda Larriba, PhD ^d, Callen Wallace, PhD ^c, Claudette St. Croix, PhD ^c, Xiuxia Zhou, PhD ^a, Jinming Zhao, PhD ^a, Shyamal Peddada, PhD ^e, Sally E. Wenzel, MD ^a,^f
^a Department of Environmental and Occupational Health, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, Pa
^b Department of Rhinology, Shengjing Hospital of China Medical University, Shenyang, China
^c Center for Biologic Imaging, School of Medicine, University of Pittsburgh Medical Center, University of Pittsburgh, Pittsburgh, Pa
^d Department of Statistics and Operations Research, Universidad de Valladolid, Valladolid, Spain
^e Department of Biostatistics, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, Pa
^f University of Pittsburgh Asthma and Environmental Lung Health Institute @UPMC, Pittsburgh, Pa

El texto completo de este artículo está disponible en PDF.

Disclosure of potential conflict of interest: S. E. Wenzel declares unrelated potential conflicts of interest in connection with consulting with Sanofi (dupilumab), AstraZeneca (tezepelumab), GSK (mepolizumab), and Knopp (dexpramipexole), as well as with multicenter research grants from AstraZeneca (tezepelumab and benralizumab), GSK (anti–IL-33), and Knopp Bioscience (dexpramipexole); in addition, she has received unrestricted research support for the Severe Asthma Research Program (unrelated to this study) from TEVA and Boehringer Ingelheim and institutional research support from Pieris. The rest of the authors declare that they have no relevant conflicts of interest.